IDH1 and central nervous system cancer: Heterozygous missense mutations, which are the major forms of IDH1 mutations observed in IDH-mutant gliomas, generate mutant IDH1 that converts isocitrate into the oncometabolite D-2-hydroxyglutarate (D-2-HG) in place of ⍺-KG [123].